Project Grant RF1AG084635
Award Date
8/15/24
Completion Date
7/31/27
Dollars Obligated
$2M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,220,647 to Weill Medical College of Cornell University to discover and develop first-in-class small molecule ligands targeting the TREM2 receptor as potential therapeutics for Alzheimer's disease. The project aims to establish a new microglial modulation strategy to treat Alzheimer's by identifying small molecules that can bind and modulate the TREM2 receptor, which plays a key role...
This $2,061,909 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Weill Medical College of Cornell University supports research on tau proteostasis and chaperone complexes in tauopathies, including Alzheimer's disease. The objective is to identify molecular mechanisms regulating tau aggregation and neurodegeneration, specifically examining how two chaperone complexes - the "foldase" complex that stabilizes tau and the...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of small-molecule degraders of the amyloid precursor protein (APP) as potential first-in-class drugs for Alzheimer's disease (AD) therapy. The total award amount is $499,883 and the award period runs from September 1, 2024 to August 31, 2025. The key products and services to be delivered under this grant include: Optimization of lead APP degrader compounds through...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,340,172 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop novel small molecule HDAC11 inhibitors as potential therapeutics for Alzheimer's disease (AD). The primary objectives are to: Explore structure-activity relationships (SAR) of the leading scaffold to create a new generation of HDAC11-selective inhibitors (Aim 1). Test the top compounds in...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,968 to Hager Biosciences, LLC to further develop small molecule inhibitors of the Kv1.3 potassium channel as potential therapeutics for Alzheimer's disease. The key objectives are to: 1) complete in vitro characterization and initial pharmaceutical profiling of lead compound analogs; 2) initiate iterative lead optimization to improve potency and drug-like properties; and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Chapman University provides $991,800.00 to conduct research on developing a blood-brain barrier (BBB) penetrating form of the protein erythropoietin (EPO) as a potential therapeutic for Alzheimer's disease (AD). The key objectives are to: Determine the optimal dose and therapeutic window for the BBB-penetrating EPO fusion protein (TFRMAB-EPO) in mouse models of AD. Assess the safety profile of chronic...
The federal Project Grant award R21AG089718, totaling $636,000.00, was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Pittsburgh. The grant aims to develop novel, orally bioavailable, and blood-brain barrier penetrant small molecule inhibitors of the NADPH oxidase 2 (NOX2) enzyme as a potential therapeutic strategy for treating Alzheimer's disease (AD) and related dementias. The key products and services to be delivered under this grant include:...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $1,012,534 to Eydis Bio, Inc. to develop orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's disease. The grant, awarded on September 15, 2024, supports identifying and optimizing TAK1 inhibitors with the desired central nervous system-related pharmacological properties, which will be further evaluated in...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC provides $994,436.00 in funding to develop novel brain-penetrant drugs for therapeutic targeting of Alzheimer's disease. The research aims to investigate the role of the histone methyltransferase G9A in Alzheimer's disease pathogenesis and the mechanism of action for a brain-penetrant G9A-targeted drug, MS1262, which has shown potential to restore cognitive and affective functions...
This federal Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 (Aging Research) aims to identify small-molecule compounds that can bind to and modify the behavior of the protein tau, which is implicated in Alzheimer's disease and other tauopathies. The $496,373 award to Jillion Therapeutics Inc. will utilize the company's DNA-encoded library drug discovery platform to screen a large library of novel compounds and identify those that can bind to monomeric and...